← All Spero Therapeutics, INC filings

Spero Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SPRO
Spero Therapeutics, INC
10-K: Spero Therapeutics Reports 2025 Net Income, Focuses on Tebipenem HBr
Spero Therapeutics achieved a net income of $8.6 million in 2025, driven by collaboration revenue, as it streamlines its pipeline to focus on the FDA approval process for tebipenem HBr with GSK.
NASDAQ
SPRO
Spero Therapeutics, INC
10-K: Spero Therapeutics Navigates Financial Uncertainty, Suspends Key Programs in Strategic Shift
Spero Therapeutics' 10-K filing reveals a company in transition, suspending SPR720 and SPR206 development while focusing on tebipenem HBr amid financial challenges and a SEC investigation.
NASDAQ
SPRO
Spero Therapeutics, INC
10-K: Spero Therapeutics Amends 2019 Equity Incentive Plan and Details Executive Compensation
Spero Therapeutics outlines amendments to its 2019 Inducement Equity Incentive Plan and provides details on executive compensation, including stock options, RSUs, and cash bonuses.